---
title: "AstraZeneca admits 8,855 new ordinary shares to London Stock Exchange main market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294709769.md"
description: "AstraZeneca admitted 8,855 new ordinary shares to the London Stock Exchange Main Market. These shares, issued under employee share schemes between July 1-31, 2026, were added via an existing block admission. Consequently, the total number of AstraZeneca's ordinary shares in issue increased to 1,551,542,244."
datetime: "2026-08-03T14:45:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294709769.md)
  - [en](https://longbridge.com/en/news/294709769.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294709769.md)
generator: "portal-rs"
---

# AstraZeneca admits 8,855 new ordinary shares to London Stock Exchange main market

-   AstraZeneca admitted 8,855 ordinary shares ($0.25 each; ISIN GB0009895292) to trading on the London Stock Exchange Main Market. \* The shares were issued from July 1-31, 2026 under the group’s employee share schemes, using an existing block admission. \* Total ordinary shares in issue rose to 1,551,033,389 following the admission. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-26-007169), on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [Key facts: LSE:AZN Zegfrovy buy; SANOVO PFS; Wan Ling Martello named](https://longbridge.com/en/news/297611733.md)
- [AstraZeneca Reports Positive Results Of SANOVO Phase III Trial In China](https://longbridge.com/en/news/297606938.md)
- [REG - AstraZeneca PLC - AstraZeneca completes agreement for Zegfrovy](https://longbridge.com/en/news/297603898.md)
- [Weekly Recap: Pipeline setbacks and Phase 3 TROPION-Urothelial04 launch](https://longbridge.com/en/news/297465352.md)
- [HUTCHMED says savolitinib plus AstraZeneca’s Tagrisso extends PFS in China Phase III SANOVO lung cancer trial](https://longbridge.com/en/news/297475889.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**